Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume
Conclusions
Patients with IPF and preserved lung volume (FVC >90% predicted) have the same rate of FVC decline and receive the same benefit from nintedanib as patients with more impaired lung volume.
Trial registration number
NCT01335464 and NCT01335477.
Source: Thorax - Category: Respiratory Medicine Authors: Kolb, M., Richeldi, L., Behr, J., Maher, T. M., Tang, W., Stowasser, S., Hallmann, C., du Bois, R. M. Tags: Open access, Interstitial lung disease Source Type: research